Tenaya Therapeutics Conference Call Summary Company Overview - **Company**: Tenaya Therapeutics (NasdaqGS:TNYA) - **Focus**: Gene therapy and small molecule development for cardiovascular diseases Key Points Clinical Programs - Tenaya has three clinical-stage programs: TN-201 and TN-401 (gene therapies) and TN-301 (small molecule HDAC6 inhibitor) [8][10] - TN-301 has shown positive preclinical data in various models, including DMD hearts and skeletal muscle, indicating broad clinical utility [9][10] - The company aims to generate data supporting pivotal studies for TN-301 while maintaining focus on gene therapy programs [8][12] Data Presentation - Recent data presented at the Muscular Dystrophy Association meeting confirmed the efficacy of TN-301 in multiple disease models, highlighting its multimodal mechanism of action [10][11] - The approval of Givinostat (Duvyzat) for DMD by Italfarmaco is noted, with Tenaya's HDAC6 inhibitor showing superior results in comparison [11][12] Financial and Strategic Position - Tenaya maintains a strong cash runway, allowing for continued development without immediate capital-intensive studies [12][29] - The company is exploring partnership opportunities to enhance value and de-risk its programs, particularly for larger indications like HFpEF [30][31] Regulatory Landscape - Tenaya is optimistic about regulatory alignment based on precedents set by other companies in similar therapeutic areas [78][79] - The company is focused on establishing approvable endpoints for accelerated approval, leveraging data from its extensive natural history study [88][89] Partnership with Alnylam - Tenaya has formed a partnership with Alnylam, receiving a $10 million upfront payment and potential for up to $1.1 billion in milestone payments [111][112] - This collaboration is seen as a validation of Tenaya's research capabilities and a strategic move to diversify its therapeutic modalities [112][113] Future Outlook - The company anticipates significant data releases over the next 18 months, which will inform its clinical development strategy and regulatory discussions [106][110] - Tenaya is positioned to leverage its diverse pipeline and partnerships to create multiple value drivers for investors [113][115] Additional Insights - The company emphasizes its commitment to gene therapies while also expanding into small molecules, indicating a balanced approach to innovation [12][113] - Tenaya's efficient use of resources allows it to pursue multiple programs simultaneously without compromising its financial stability [29][30]

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: ...